Skip to main content

Uveal Melanoma Case Statement

Page 1

The Uveal Melanoma Program


The Challenge Uveal melanoma is the most common type of cancer in the adult eye, affecting two thousand Americans per year. It is also one of the most aggressive and complex types of cancer—one that is largely unaffected by traditional treatments of radiation and chemotherapy.

Jefferson: A National Destination While the incidence of uveal melanoma is low, the chances are high that patients with advanced stages of the disease will seek treatment at Jefferson. Since 1999, we have seen approximately 100 new patients every year with metastatic uveal melanoma, about two-thirds of whom travel from outside of the tri-state area for treatment. Home to a multidisciplinary team of some of the world’s foremost experts in the field, our NCI-designated Sidney Kimmel Cancer Center (SKCC) is a national referral center for uveal melanoma patients, particularly for treatments directed at the liver—the most common site of metastasis for this unique patient population.

The Need for Research While we are currently pursuing multiple methods to study and treat uveal melanoma, we are only beginning to scratch the surface in our understanding of the disease. Recently, this rare form of cancer has begun to exhibit new incidence behaviors, uniquely affecting patients residing in the two U.S. cities of Auburn, Alabama and Huntersville, North Carolina. This type of geographical accumulation has never been observed before, and represents a new frontier for uveal melanoma research. Every discovery brings us closer to a new treatment, a new standard of care, even a cure. And philanthropic support is a powerful catalyst for new discoveries and breakthroughs.

2


3


4


Our Vision

At Jefferson’s Sidney Kimmel Cancer Center, our vision is clear—we are working to establish an international standard of care for this devastating disease. We have a proven track record for pioneering new therapies and treatments for metastatic uveal melanoma patients. Our multidisciplinary program is one of only a few across the country and, as a nationally ranked referral center, our program is one of the most trusted in the United States. To make this vision a reality, we are tireless in our pursuit of three strategic priorities: provide the highest quality of care to our patients and their loved ones, pursue bold new research opportunities, and train the future leaders of the discipline. Every step we take today brings us closer to a cure tomorrow. Philanthropy is the foundation upon which these priorities stand, serving as a vital catalyst for trailblazing work that is leading to more breakthroughs, more therapies, and more hope for uveal melanoma patients. By investing in Jefferson, you place the next level of understanding, prevention, and treatments all within our reach. This is the future of cancer care, and it’s powered by you. The next breakthrough, the next treatment—you make it possible.

5


The Uveal Melanoma Team at Jefferson Takami Sato, MD, PhD As the Director of the Metastatic Uveal Melanoma Program, Dr. Takami Sato heads one of the few programs in the United States treating melanoma originating in the eye. He has devoted his career to improving understanding of this disease and developing new treatments, particularly for patients who are not eligible for surgery. Dr. Sato’s studies focus on cancer immunotherapy, and his clinical trials involving a procedure called immunoembolization have shown promising results. Dr. Sato is building on these outcomes as he continues to develop novel methods of treating uveal melanoma and delaying its progression.

6

Marlana Orloff, MD Dr. Marlana Orloff is a rising star in the field and a true embodiment of Jefferson’s “care with caring” ethos. She joined the faculty in 2015 as Assistant Professor of Medical Oncology treating melanomas of the skin and eye. In addition to her clinical work, she has written numerous peer-reviewed articles and publications, and is a nationally renowned guest lecturer. Dr. Orloff is also a member of the Society for Immunotherapy of Cancer, and the American Association for Cancer Research.


Renee Zalinsky, RN, OCN Renee Zalinsky is the first point of contact for Jefferson’s metastatic ocular melanoma patients and their loved ones, providing hands-on and compassionate support through every stage of their cancer journey. Whether scheduling appointments or keeping patients abreast of the latest clinical trials, Renee works tirelessly to handle the many details associated with our patients’ care, so that they can focus on what matters most—getting healthy.

Carin F. Gonsalves, MD Dr. Carin F. Gonsalves is Assistant Professor and Co-Director of the Division of Interventional Radiology. She is a revered clinician, researcher, and lecturer. Dr. Gonsalves is the recipient of numerous scientific, editorial, and academic awards, and is consistently recognized as one of CastleConnolly’s Top Doctors. She is a member of the American College of Radiology, the Radiology Society of North America, and the Society of Interventional Radiology.

Andrew Aplin, PhD Dr. Andrew Aplin is the Kalbach-Newton Professor of Cancer Research, overseeing the basic science programs, pilot funding for laboratorybased research projects, and recruitment of basic scientists into SKCC. On a national level, Dr. Aplin is a member of the grant review panel for the Melanoma Research Alliance and a member of the Scientific Advisory Council (SAC) for the Melanoma Research Foundation. He is Associate Editor of Pigment Cell and Melanoma Research, and serves on the editorial boards of Cancer Research and Molecular Cancer Research.

David Eschelman, MD Dr. David Eschelman is Professor and CoDirector of the Division of Interventional Radiology. He is a nationally recognized expert who has been named one of Philadelphia Magazine’s Top Docs in 2017 and 2018, and is consistently ranked among Castle-Connolly’s Top Doctors in Vascular & Interventional Radiology. He is a member of the Society of Interventional Radiology, author of many peer-reviewed articles and publications, and a sought-after guest lecturer.

Robert Adamo, MD Dr. Robert Adamo is Assistant Professor of Radiology and Associate Program Director of the Fellowship and Residency Interventional Radiology program. He is a member of the American College of Radiology, the Radiology Society of North America, the Society of Interventional Radiology, and the Philadelphia Angiography and Interventional Radiology Society.

Jeff Benovic, PhD Dr. Jeff Benovic is the Thomas Eakins Endowed Professor and the Chair of Biochemistry and Molecular Biology. He is an internationally recognized researcher focusing on understanding the molecular and cellular basis of G protein-coupled receptor (GPCR) signaling. Mutations in GPCR signaling are found in approximately 98% of uveal melanoma cases. Dr. Benovic’s work is pivotal to identifying potential therapeutic targets for this patient population.

7


A uveal melanoma diagnosis is life changing for patients and their loved ones. We understand how overwhelming a cancer diagnosis can be, which is why we strive to be more than just a medical team. We are an ally, working diligently to coordinate and advocate on our patients’ behalf from diagnosis through treatment and beyond.

A Hands-on, Holistic Approach

Novel, Next-Generation Therapies

Every step of cancer treatment, from a cancer diagnosis to forming a survivorship plan, comes with unique needs and issues that can be overwhelming for patients and their loved ones.

Jefferson is home to a number of innovative treatments for metastatic uveal melanoma, including immunoembolization, transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), and drug-eluting beads.

“I try to encourage them to take it one day at a time, and our team makes it a point to work around whatever is going on in their lives,” says Renee Zalinsky. “If they want to take a trip or they’re planning to go to a wedding or anniversary party, we do our best to work the treatment around that. Over time, these patients become part of our family.” Philanthropy empowers our team to provide myriad support services that maximize our patients’ quality of life while they are in our care, including legal guidance, financial planning, psychotherapeutic services, transportation, and lodging support.

8

Few centers in the country match the breadth of our treatment options. In fact, none offers immunoembolization, which was developed at Jefferson and has been shown to markedly increase length of survival with modest toxicities. Philanthropy presents a special opportunity to fuel the development of these novel therapies, improving the care and quality of life for current and future patients. It causes a ripple effect of hope and healing that helps to create future survivors.

“Over time, these patients become part of our family.” Renee Zalinsky

A Compassionate Team As we look towards the future, it is our goal to expand our dedicated team with key recruits providing critical psychosocial and support services. In particular, we will recruit patient navigators who will serve as liaisons to our patients, helping them set up appointments, access lab results, communicate with physicians, get to and from appointments, arrange referrals and follow up after treatments and procedures. These patient navigators will be crucial members of the team, ensuring that all metastatic uveal patients will continue to receive the best care experience possible.


“The patient is the center of everything we do. We tailor treatments to what’s appropriate for each patient, being mindful of what’s going on in their lives beyond their disease.” - Takami Sato, MD, PhD Director, Metastatic Uveal Melanoma Program

Made Possible By You:

Your generosity facilitates the best patient-centered clinical care from a multidisciplinary medical team. By combining world-renowned physicians from an array of disciplines and specialties, we can provide the best treatments, tailor-made for each patient. Your gift has the power to help us continue creating innovative solutions for future generations of uveal melanoma patients.

9


In the fight against uveal melanoma, science matters. From molecular breakthroughs to innovative therapies and technologies, every discovery made in the lab today plays a crucial role in curing cancer tomorrow. By supporting our research into uveal melanoma, you are creating new opportunities for discovery.

Translational Research

Clinical Trials All treatments that are now standard of care were once considered cutting-edge, and all were pioneered through clinical research. At SKCC, we are steadfast in our dedication to clinical research, particularly for metastatic uveal melanoma. In fact, we are in the top 5% of cancer centers nationwide for clinical trial

As the backbone of medical innovation, translational

enrollment.

research uncovers the cures of tomorrow and saves lives

“We are committed to designing and providing

today. This research provides the empirical evidence

the right treatment for the right patient at the

necessary to advance scientific knowledge and to

right time,” says Dr. William Kevin Kelly, associate

rapidly translate discoveries into new drugs, therapies,

director of clinical research at SKCC. “The more

and technologies. Philanthropy is invaluable to our

support we have for clinical trials and novel care,

research efforts, serving as a powerful catalyst

the more successful we are in precisely tailoring

for breakthroughs and innovations from the

treatments.”

bench to the bedside.

The patient data garnered from these studies will be critical to broadening our understanding and treatment of uveal melanoma.

10


ImmTAC - A Novel Phase One Drug for Metastatic Uveal Melanoma In January 2016, the U.S. Food and Drug Administration (FDA) granted ImmTAC (Immune mobilizing mTCR Against Cancer) an Orphan Drug designated for the treatment of uveal melanoma. Jefferson’s Sidney Kimmel Cancer Center is one of five sites in the world, and only three sites in the United States, currently offering a clinical trial. This type of approach is potentially a breakthrough treatment for many different types of cancer.

Immunology Two gene mutations are reported to cause uveal melanoma development. Dr. Sato’s current research efforts are devoted to developing a cancer vaccine that stimulates a patient’s immune system to target these mutations and eliminate the cancer cell, preventing recurrence.

Local Attacks on Metastases In this approach, natural killer cells are obtained from a healthy donor and infuse them into the patient with a liver metastasis. Because the patient’s own natural killer cells may be weak or not effectively identifying the cancer cells, this concept will test the effectiveness of the healthy donor’s cells to target and attack cancer cells. This approach is currently in the early clinical stages.

Personalized Medicine The uveal melanoma team has developed a first-in-field approach to surgically implant a patient’s tumor into a mouse model to test the tumor’s molecular characteristics and drug sensitivity. As each patient’s tumor has unique characteristics that affect its response to treatments, this practice allows the team to develop a customized treatment plan for metastatic uveal melanoma. So far, the team has an implantation success rate of greater than 80 percent – the highest success rate among those who are attempting this technology.

Dormancy Uveal melanoma sometimes develops metastases decades after diagnosis and treatment. The mechanism of this late recurrence has not been well studied. Dr. Aplin’s laboratory has identified a specific agent with the potential to induce dormancy in metastatic uveal melanoma cells and a currently compiling the information necessary to develop a clinical trial focused on inducing dormancy.

Made Possible By You:

The methods listed above are only a handful that the uveal melanoma team is pursuing. Through philanthropy, you not only strengthen our research endeavors, you make them possible. Your generosity is the catalyst that empowers our researchers to uncover insights to better predict, prevent, and treat uveal melanoma. 11


Education At Jefferson, we have the best team working to treat and cure uveal melanoma. As we look toward the future, it is critical to recruit and retain the rising stars of the coming generations. Endowment funding provides a competitive edge that enables us to do so. Vital to the future of Jefferson’s financial stability, endowments ensure future opportunities for the pursuit of innovative research; provide training and education for future generations of world-class physicians, health providers, and scientists; and accelerate the path to achieving the best national and international standing in uveal melanoma research and clinical care. With an endowment, you have the power to make a difference that lasts in perpetuity, leaving a legacy of hope and healing that will be felt for generations to come.

12


Attracting Premier Faculty Endowed chairs and professorships are the most prestigious

faculty

appointments

at

Jefferson.

Considered as a pillar of academic medicine, they markedly strengthen our ability to recruit and retain the best physicians, clinicians, and scientists in the world. Reserved for leaders in their fields, endowed positions signify Jefferson’s belief in a faculty member’s past contributions and future promise. They recognize the holder who has earned the distinction, the namesake who is being honored, and the donor who made the endowment possible.

Training the Next Generation Innovation in the health sciences depends on the constant exchanges between prominent researchers and gifted students. For aspiring clinicians and researchers, the beginning of a distinguished career often involves specialized training and research opportunities. Endowment funding for fellowships provides the support necessary to train the future leaders of the discipline.

Made Possible By You:

You can help us transform the future of cancer care by ensuring we have the best people on our team. Your gift fosters the careers of the most accomplished physicians and researchers. Your generosity has the power to ensure that Jefferson always has the brightest minds focused on the fight against uveal melanoma.

13


14


W

e are steadfast in our mission to make a better world for patients and families affected by uveal melanoma. But without visionary donors to drive innovative and forwardthinking luminary programs, they are likely to remain merely big ideas— tantalizingly out of reach for physicians and patients alike. You are the difference. The next breakthrough, the next treatment—you make it possible. With a gift to Jefferson, you not only support our pathbreaking work—you can leave a legacy that will inspire future faculty and patients. You give people hope. With the brightest minds, boldest ideas, and a reputation for nextgeneration and compassionate care, we are uniquely poised to make the most of your philanthropic investment, quickly transforming your generosity into tangible, life-saving medical successes. An investment in this program is an investment in our patients. Thank you for helping them achieve the best possible quality of life.

“Dr. Sato is on the verge of something really big. If he has the funds to continue discovering why the clinical trials are working for us, then he can help more people. Research is really the key to curing uveal melanoma.” -Terry Willoughby Grateful Patient

15


TO LEARN MORE,

CONTACT Jonathan Agree Vice President of Development Sidney Kimmel Cancer Center and Clinical Programs Office of Institutional Advancement Thomas Jefferson University and Jefferson Health 215-503-6058 jonathan.agree@jefferson.edu

Office of Institutional Advancement 125 S. 9th St, Suite 600 Philadelphia, PA 19107 Giving.Jefferson.edu

STRAT-18-079


Turn static files into dynamic content formats.

Create a flipbook
Uveal Melanoma Case Statement by zackworsham - Issuu